文献速递妇科肿瘤

他拉唑帕利联合阿维鲁单抗治疗复发性错配修复功能完整型子宫内膜癌患者的疗效评估

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
PubMed 文献 · JAMA Oncol · 2022-01-01

这项研究者发起的开放标签单臂两阶段2期非随机对照试验在美国4家机构纳入35例复发性错配修复功能完整型子宫内膜癌患者,接受他拉唑帕利1 mg口服每日一次联合阿维鲁单抗10 mg/kg静脉每2周一次治疗。9例(25.7%)获得临床获益,4例(11.4%)确认客观缓解(均为部分缓解),8例(22.9%)6个月无进展生存。同源重组修复基因改变与临床获益相关,肿瘤突变负荷、肿瘤浸润淋巴细胞及PD-L1状态与临床获益无关。

要点

  • 他拉唑帕利联合阿维鲁单抗在复发性错配修复功能完整型子宫内膜癌中达到预设的进一步评估标准。
  • 9例(25.7%)获得临床获益,4例(11.4%)确认客观缓解(4例部分缓解),8例(22.9%)6个月无进展生存。
  • 同源重组修复基因改变与临床获益相关,肿瘤突变负荷、肿瘤浸润淋巴细胞及PD-L1状态与临床获益无关。

核心结论

  • 这项非随机对照试验结果提示,阿维鲁单抗联合他拉唑帕利表现出有利的毒性特征,并达到预设标准,值得在错配修复功能完整型子宫内膜癌中进一步评估。
  • 免疫基因组分析提供的见解可能为正在进行的和未来的聚腺苷二磷酸核糖聚合酶与PD-L1抑制剂联合治疗子宫内膜癌的研究提供信息。

研究设计与样本

  • 研究者发起的开放标签单臂两阶段2期非随机对照试验,在美国4家机构开展。
  • 关键纳入标准包括可测量病灶、既往治疗线数不限以及所有子宫内膜癌组织学类型。
  • 35例女性患者接受方案治疗,平均(SD)年龄67.9(8.41)岁。
  • 干预为他拉唑帕利1 mg口服每日一次联合阿维鲁单抗10 mg/kg静脉每2周一次,直至疾病进展或不可接受的毒性反应。
  • 统计设计针对客观缓解率和6个月无进展生存率两个共同主要终点,两阶段设计允许因无效提前终止。

主要发现

  • 35例患者中9例(25.7%)在达到两个共同主要终点中至少一个后获得临床获益。
  • 4例(11.4%)显示确认的客观缓解率(4例部分缓解)。
  • 8例(22.9%)在6个月时无进展生存。
  • 最常见的3级和4级治疗相关毒性反应为贫血(16例[46%])、血小板减少(10例[29%])和中性粒细胞减少(4例[11%]);没有患者因毒性反应停止治疗。
  • 伴有同源重组修复基因改变的肿瘤与阿维鲁单抗联合他拉唑帕利治疗的临床获益相关;肿瘤突变负荷、肿瘤浸润淋巴细胞和PD-L1状态与临床获益无关。

关键数值与推荐

  • 预设探索性目标包括通过靶向面板下一代测序和免疫组织化学确定的免疫基因组特征与疗效的关联。
  • 两个共同主要终点为客观缓解率和6个月无进展生存率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although the activity of pembrolizumab and lenvatinib (the only US Food and Drug Administration-approved immunotherapy for mismatch repair proficient endometrial cancer [MMRP EC]) is compelling, there are no biomarkers of response and most patients do not tolerate, do not respond to, or develop resistance to this regimen, highlighting the need for additional, potentially biomarker-driven therapeutic approaches for patients with recurrent MMRP EC. OBJECTIVE: To assess the potential positive outcomes and safety of the combination of the polyadenosine diphosphate-ribose polymerase inhibitor talazoparib and the programmed cell death ligand 1 (PD-L1) inhibitor avelumab in recurrent MMRP EC. DESIGN, SETTINGS, AND PARTICIPANTS: This investigator-initiated, open-label, single-arm, 2-stage, phase 2 study nonrandomized controlled trial patients at 4 institutions in the US. Key eligibility criteria included measurable disease, unlimited prior therapies, and all endometrial cancer histologies. INTERVENTIONS: Talazoparib, 1 mg, orally, daily, and avelumab, 10 mg/kg, intravenously, every 2 weeks, were administered until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: Statistical considerations were developed for 2 coprimary objectives of objective response rate and rate of progression-free survival at 6 months, with a 2-stage design that allowed for early discontinuation for futility. Prespecified exploratory objectives included the association of immunogenomic features (determined by targeted-panel next-generation sequencing and immunohistochemistry) with activity. RESULTS: Thirty-five female patients (mean [SD] age, 67.9 [8.41] years) received protocol therapy; 9 (25.7%) derived clinical benefit after meeting at least 1 of the 2 coprimary end points. Four patients (11.4%) exhibited confirmed objective response rates (4 partial responses), and 8 (22.9%) survived progression free at 6 months. The most common grade 3 and 4 treatment-related toxic effects were anemia (16 [46%]), thrombocytopenia (10 [29%]), and neutropenia (4 [11%]); no patient discontinued receipt of therapy because of toxic effects. Tumors with homologous recombination repair alterations were associated with clinical benefit from treatment with avelumab and talazoparib. Tumor mutational burden, tumor-infiltrating lymphocytes, and PD-L1 status were not associated with clinical benefit. CONCLUSIONS AND RELEVANCE: The results of this nonrandomized controlled trial suggest that treatment with avelumab and talazoparib demonstrated a favorable toxic effect profile and met the predetermined criteria to be considered worthy of further evaluation in MMRP EC. Immunogenomic profiling provided insights that may inform ongoing and future studies of polyadenosine diphosphate-ribose polymerase and PD-L1 inhibitor combinations in endometrial cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02912572.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Konstantinopoulos PA, Gockley AA, Xiong N, et al. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022. PMID: 35900726. doi:10.1001/jamaoncol.2022.2181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。